HubSpot Inc vs Revvity Inc — how do they compare? HubSpot Inc trades at $228.3 (market cap $11.56B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and Revvity Inc for 12 Days on average.
| HUBS | RVTY | |
|---|---|---|
Market Cap | $11.56B | $16.98B |
Volume | 1,891,287 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $494.58 | $157.36 |
52-Week Low | $170.39 | $82.26 |
Typical Hold Time | 78 Days | 12 Days |
Enterprise Value | $10.46B | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $228.30, up 3.63% with strong technical momentum and bullish moving averages. The company demonstrates robust revenue growth, reaching $3.13B in 2025 with improving profitability, though valuation ratios remain elevated. Recent analyst day highlighted AI strategy enhancements and margin expansion targets, while institutional buying and positive earnings beats support investor confidence.
Outlook remains positive with 57% analyst buy ratings and $243.65 consensus target, though risks include high P/E ratio, competitive pressures, and potential AI disruption concerns. The stock offers growth exposure with solid cash flow generation but requires monitoring of execution against ambitious margin targets.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →